Neuren thinks big
Wednesday, 16 July, 2008
Neuren Pharmaceuticals [ASX: NEU] has concluded patient recruitment and dosing for its Phase III clinical trial of Glypromate, a therapeutic designed to reduce brain impairment after major heart surgery.
The recruitment of 320 patients has been concluded ahead of schedule, and Neuren is expecting to release provisional efficacy results before the end of the year.
Up to a third of patients suffer cognitive impairment three months after major heart surgery, and there is currently no approved treatment to prevent it.
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
Over-the-counter pain relievers may improve concussion recovery
People who take over-the-counter pain relievers after a concussion may recover faster than those...